AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23580597 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise for 60 min at 60‐65% aerobic capacity (E)
Number of subjects: 3
Study 23580597 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐intensity resistance exercise for 60 min (R)
Number of subjects: 3
Study 23580597 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control trial (C)
Number of subjects: 3
Study 21419411 — intervention group
Group type: EXPERIMENTAL
Intervention: SAFE or SORRY? programme
Number of subjects: 2593
Study 21419411 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2593
Study 19732495 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole 1 g
Number of subjects: 50
Study 17356086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep laboratory RP (LRP)
Number of subjects: 62
Study 17356086 — intervention group
Group type: EXPERIMENTAL
Intervention: Home RP (HRP)
Number of subjects: 62
Study 17356086 — intervention group
Group type: EXPERIMENTAL
Intervention: Home RP (HRP) using total recording time (RDITRT)
Number of subjects: 62
Study 17356086 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for LRP and HRP
Number of subjects: 62
Study 15142199 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (Proton-pump inhibitor) for 4 weeks
Number of subjects: 232
Study 15142199 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 232
Study 11465668 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 399
Study 11465668 — intervention group
Group type: COMPARATOR
Intervention: Control (unvaccinated)
Number of subjects: 399
Study 10861309 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl palmitate (300000 IU daily for 1 year followed by 150000 IU for a 2nd year)
Number of subjects: 2592
Study 10861309 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg daily for 2 years)
Number of subjects: 2592
Study 10861309 — intervention group
Group type: EXPERIMENTAL
Intervention: Both retinyl palmitate and N-acetylcysteine
Number of subjects: 2592
Study 10861309 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 2592
Study 9188924 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 19
Study 9188924 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled cromoglycate
Number of subjects: 19
Study 9188924 — intervention group
Group type: EXPERIMENTAL
Intervention: Methacholine reactivity measurement
Number of subjects: 19
Study 1366257 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg o.d.
Number of subjects: 58
Study 1366257 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg o.d.
Number of subjects: 58
Study 1366257 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during run-in period)
Number of subjects: 58
Study 3933619 — intervention group
Group type: EXPERIMENTAL
Intervention: CR3 retinal camera
Number of subjects: 0
Study 3933619 — intervention group
Group type: EXPERIMENTAL
Intervention: CR2 retinal camera
Number of subjects: 0
Study 3933619 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmoscopy (control)
Number of subjects: 0
Study 30328495 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontourniquet group
Number of subjects: 81
Study 30328495 — intervention group
Group type: COMPARATOR
Intervention: Tourniquet group
Number of subjects: 81
Study 29505381 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional cash transfers (Family Rewards)
Number of subjects: 2377
Study 29505381 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2377
Study 27091348 — intervention group
Group type: EXPERIMENTAL
Intervention: Online communication tool for patients
Number of subjects: 78
Study 27091348 — intervention group
Group type: EXPERIMENTAL
Intervention: Affective communication behaviour of the health care professional
Number of subjects: 78
Study 27091348 — intervention group
Group type: EXPERIMENTAL
Intervention: Information exchange
Number of subjects: 78
Study 23893503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavior therapy (CBT)
Number of subjects: 134
Study 22385030 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-shave moisturizers containing glycerine and emollients
Number of subjects: 0
Study 22385030 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporation of specific ingredients such as niacinamide
Number of subjects: 0
Study 20523287 — intervention group
Group type: EXPERIMENTAL
Intervention: Early control of the distal internal carotid artery (group A, N=12)
Number of subjects: 28
Study 20523287 — intervention group
Group type: COMPARATOR
Intervention: Traditional CEA with dissection of the total carotid bifurcation (group B, N=17)
Number of subjects: 28
Study 20523287 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 28
Study 17629731 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 44
Study 17629731 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 44
Study 16188771 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal milk protein intake from cheese during pregnancy
Number of subjects: 112
Study 16188771 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal consumption of raw milk products during lactation
Number of subjects: 112
Study 16188771 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal cheese consumption
Number of subjects: 112
Study 11919120 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Protein (HP) diet (28% protein, 42% carbohydrate)
Number of subjects: 26
Study 11919120 — intervention group
Group type: COMPARATOR
Intervention: Low-Protein (LP) diet (16% protein, 55% carbohydrate)
Number of subjects: 26
Study 10639847 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (6 mg)
Number of subjects: 40
Study 10639847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8521296 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide
Number of subjects: 30
Study 8521296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2290135 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 13 weeks
Number of subjects: 0
Study 2290135 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 0
Study 2290135 — intervention group
Group type: COMPARATOR
Intervention: Non-aerobic control
Number of subjects: 0
Study 31550844 — intervention group
Group type: EXPERIMENTAL
Intervention: GEDI-guided fluid resuscitation
Number of subjects: 41
Study 31550844 — intervention group
Group type: COMPARATOR
Intervention: Early goal-directed therapy
Number of subjects: 41
Study 27153360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg (1 mgQ4 wk)
Number of subjects: 83
Study 27153360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg (3 mgQ4 wk)
Number of subjects: 83
Study 27153360 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulranumab 10 mg (10 mgQ4 wk)
Number of subjects: 83
Study 27153360 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 25826143 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate extract (1000 mg capsule, 7 days/week for 6 months)
Number of subjects: 33
Study 25826143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (noncaloric capsule, 7 days/week for 6 months)
Number of subjects: 33
Study 24079625 — intervention group
Group type: EXPERIMENTAL
Intervention: Gomco circumcision clamp plus tissue adhesive
Number of subjects: 200
Study 24079625 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgical circumcision with suturing
Number of subjects: 200
Study 21857908 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention aimed at social bonding
Number of subjects: 100
Study 21857908 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-participants)
Number of subjects: 100
Study 19213793 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-500,001 1.0 mg b.i.d.
Number of subjects: 209
Study 19213793 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-500,001 0.1 mg b.i.d.
Number of subjects: 209
Study 19213793 — intervention group
Group type: EXPERIMENTAL
Intervention: UK-500,001 0.4 mg b.i.d.
Number of subjects: 209
Study 19213793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 17227996 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1200 mg of elemental calcium daily for 4 years)
Number of subjects: 930
Study 17227996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 930
Study 17227996 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 930
Study 15472179 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (2.5 mg daily)
Number of subjects: 585
Study 15472179 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (5 mg daily)
Number of subjects: 585
Study 15472179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 585
Study 11558856 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg, once daily)
Number of subjects: 495
Study 11558856 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80 mg, once daily)
Number of subjects: 495
Study 9499281 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (100 mg/kg/24 h)
Number of subjects: 288
Study 9499281 — intervention group
Group type: COMPARATOR
Intervention: Ceftizoxime (100 mg/kg/24 h)
Number of subjects: 288
Study 7871233 — intervention group
Group type: EXPERIMENTAL
Intervention: Preworkshift meeting reviewing five randomly selected interactions recorded during the previous day's shift, including self-evaluation, praise, corrective feedback, and role-play.
Number of subjects: 2
Study 7871233 — intervention group
Group type: EXPERIMENTAL
Intervention: Review of tape-recorded interactions prior to randomly selected shifts (for Dana) and supplemented with graphic feedback (for Rick).
Number of subjects: 2
Study 7871233 — intervention group
Group type: EXPERIMENTAL
Intervention: No tape recorder worn during the second observation period.
Number of subjects: 2
Study 7871233 — intervention group
Group type: EXPERIMENTAL
Intervention: Final phase without tape recorder and follow-up observations 4 to 8 weeks later.
Number of subjects: 2
Study 3048373 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy supplementation (1.95 MJ or 465 kcal per day)
Number of subjects: 0
Study 3048373 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy supplementation (218 kJ or 52 kcal per day)
Number of subjects: 0
Study 3048373 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline home diet average 6.28 MJ or 1500 kcal)
Number of subjects: 0
Study 31787434 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiaortic ultrasound performed by the surgeon using a high frequency (>7 MHz) ultrasound transducer.
Number of subjects: 1150
Study 31787434 — intervention group
Group type: COMPARATOR
Intervention: No epiaortic ultrasound performed (Control group).
Number of subjects: 1150
Study 31269876 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoblock polyethylene design (Group A)
Number of subjects: 53
Study 31269876 — intervention group
Group type: COMPARATOR
Intervention: Modular polyethylene design (Group B)
Number of subjects: 53
Study 31269876 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Monoblock and Modular designs
Number of subjects: 53
Study 31269876 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 53
Study 28299472 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostomy rod use
Number of subjects: 320
Study 28299472 — intervention group
Group type: COMPARATOR
Intervention: No ostomy rod use
Number of subjects: 320
Study 25108027 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination at 8 weeks of age
Number of subjects: 56
Study 25108027 — intervention group
Group type: COMPARATOR
Intervention: BCG vaccination at birth
Number of subjects: 56
Study 23551723 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (1 day/week)
Number of subjects: 79
Study 23551723 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training (more than 1 day/week)
Number of subjects: 79
Study 23551723 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 79
Study 22174778 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich supplementation
Number of subjects: 22
Study 22174778 — intervention group
Group type: COMPARATOR
Intervention: DHA-rich supplementation
Number of subjects: 22
Study 18318566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg once daily
Number of subjects: 0
Study 18318566 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of dutasteride and tamsulosin
Number of subjects: 0
Study 18318566 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (Dutasteride + Tamsulosin)
Number of subjects: 0
Study 18318566 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0
Study 16432269 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-mg rizatriptan orally disintegrating tablet with water (ODTc)
Number of subjects: 24
Study 16432269 — intervention group
Group type: COMPARATOR
Intervention: 10-mg rizatriptan orally disintegrating tablet without water (ODTs)
Number of subjects: 24
Study 16432269 — intervention group
Group type: COMPARATOR
Intervention: 10-mg rizatriptan tablet
Number of subjects: 24
Study 12925545 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized support system for symptom management
Number of subjects: 52
Study 12925545 — intervention group
Group type: COMPARATOR
Intervention: Control group (no computerized support system)
Number of subjects: 52
Study 11012556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (30 microg ethinylestradiol and 75 microg gestodene)
Number of subjects: 9
Study 11012556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 8703457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (F) 1 microgram/kg
Number of subjects: 44
Study 8703457 — intervention group
Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 44
Study 8703457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl (F)
Number of subjects: 44
Study 1393074 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml of 1% lignocaine at 20 degrees C
Number of subjects: 40
Study 1393074 — intervention group
Group type: COMPARATOR
Intervention: 1 ml of 1% lignocaine at 37 degrees C
Number of subjects: 40
Study 3996632 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic intervention (interview with psychotherapist)
Number of subjects: 20
Study 3996632 — intervention group
Group type: COMPARATOR
Intervention: Control group (no psychotherapeutic intervention)
Number of subjects: 20
Study 29699812 — intervention group
Group type: EXPERIMENTAL
Intervention: High-cholesterol/high-fat diet (HChF)
Number of subjects: 14
Study 27003829 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal doses of renin-angiotensin system blockers (monotherapy or dual blockade)
Number of subjects: 101
Study 27003829 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest levels of TNFR1
Number of subjects: 101
Study 27003829 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline proteinuria
Number of subjects: 101
Study 27003829 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-angiotensin system blockers treatment
Number of subjects: 101
Study 25822242 — intervention group
Group type: EXPERIMENTAL
Intervention: JASPER intervention
Number of subjects: 86
Study 25822242 — intervention group
Group type: COMPARATOR
Intervention: PEI intervention
Number of subjects: 86
Study 23160758 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 50 U
Number of subjects: 73
Study 23160758 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 100 U
Number of subjects: 73
Study 23160758 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 200 U
Number of subjects: 73
Study 23160758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 22003217 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane‐remifentanil
Number of subjects: 40
Study 22003217 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol‐remifentanil
Number of subjects: 40
Study 22003217 — intervention group
Group type: COMPARATOR
Intervention: Cerebral State Monitor™ (CSM)
Number of subjects: 40
Study 18555574 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebaudioside A (1000mg/day for 4 weeks)
Number of subjects: 100
Study 18555574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 16472283 — intervention group
Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg once daily for 7 days
Number of subjects: 13
Study 16472283 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 500 mg twice daily for 7 days
Number of subjects: 13
Study 16472283 — intervention group
Group type: EXPERIMENTAL
Intervention: levofloxacin 500 mg once daily for 7 days
Number of subjects: 13
Study 16472283 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 13
Study 15290734 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g MaxEPA (omega-3 fish oils)
Number of subjects: 52
Study 15290734 — intervention group
Group type: COMPARATOR
Intervention: 3 mg copper
Number of subjects: 52
Study 15290734 — intervention group
Group type: COMPARATOR
Intervention: Placebo fish oil
Number of subjects: 52
Study 15290734 — intervention group
Group type: COMPARATOR
Intervention: Placebo copper
Number of subjects: 52
Study 11263764 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training (50-70% of repetition maximum, all major muscle groups, twice a week)
Number of subjects: 70
Study 11263764 — intervention group
Group type: COMPARATOR
Intervention: Range of motion exercises (without resistance, twice a week)
Number of subjects: 70
Study 9307638 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) modified grid laser photocoagulation
Number of subjects: 91
Study 9307638 — intervention group
Group type: COMPARATOR
Intervention: Argon green (514 nm) modified grid laser photocoagulation
Number of subjects: 91
Study 8519111 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic antibiotics (SAs)
Number of subjects: 1688
Study 8519111 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin bone cement (GBC)
Number of subjects: 1688
Study 3548440 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (5.1 mg/min)
Number of subjects: 0
Study 3548440 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 0
Study 29610408 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving intervention services
Number of subjects: 147
Study 29610408 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived developmental delay
Number of subjects: 147
Study 29610408 — intervention group
Group type: EXPERIMENTAL
Intervention: Not having a sibling in the home
Number of subjects: 147
Study 29610408 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with at least a college education
Number of subjects: 147
Study 29610408 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels of parental stress
Number of subjects: 147
Study 26211422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and scapulothoracic stabilization exercises with connective tissue massage (Group 1, n = 30)
Number of subjects: 60
Study 26211422 — intervention group
Group type: COMPARATOR
Intervention: Cervical and scapulothoracic stabilization exercises without connective tissue massage (Group 2, n = 30)
Number of subjects: 60
Study 24901080 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose load
Number of subjects: 0
Study 20146111 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-based symptom management intervention (seven peer-led sessions over seven weeks)
Number of subjects: 89
Study 20146111 — intervention group
Group type: COMPARATOR
Intervention: Control condition (received a copy of HIV Symptom Management Strategies: A Manual for People Living with HIV/AIDS)
Number of subjects: 89
Study 18979975 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-smoking PSAs
Number of subjects: 166
Study 16477955 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert group (MSLT > 10 minutes)
Number of subjects: 50
Study 16477955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleepy-Alert group (MSLT < 7 minutes, subjective sleepiness < 1 SD above mean)
Number of subjects: 50
Study 16477955 — intervention group
Group type: COMPARATOR
Intervention: Sleepy-Sleepy group (MSLT < 7 minutes, subjective sleepiness > 1 SD above mean)
Number of subjects: 50
Study 16477955 — intervention group
Group type: EXPERIMENTAL
Intervention: Alert group
Number of subjects: 50
Study 16477955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleepy-Alert group
Number of subjects: 50
Study 11709484 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopaminergic medication
Number of subjects: 0
Study 9146328 — intervention group
Group type: EXPERIMENTAL
Intervention: Duraflo II heparin-coated circuit (n = 10)
Number of subjects: 40
Study 9146328 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmeda BioActive Surface heparin-coated circuit (n = 10)
Number of subjects: 40
Study 9146328 — intervention group
Group type: COMPARATOR
Intervention: Uncoated circuit (n = 10)
Number of subjects: 40
Study 8174879 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of GRP at dosages of 10, 40, and 160 pmol/kg per hour
Number of subjects: 0
Study 8174879 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study 2885344 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 to 30 mg daily
Number of subjects: 24
Study 2885344 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 to 30 mg daily
Number of subjects: 24
Study 2885344 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 29494855 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg daily for 90 days)
Number of subjects: 404
Study 29494855 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional secondary preventive therapy for ischemic stroke)
Number of subjects: 404
Study 27728850 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV vaccination after Pap test
Number of subjects: 0